SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the pricing of an underwritten public offering of shares of its common stock, which is expected to result in gross proceeds of approximately $550 million, before deducting estimated offering expenses. The underwriter may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the New York Stock Exchange, in the over-the-counter market, or to dealers in negotiated transactions or in a combination of such methods of sale or otherwise at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to prevailing market prices, or at negotiated prices. In connection with the Offering, Catalent has granted the underwriter an option for 30 days to purchase up to an additional approximately $82.5 million of shares of its common stock. Subject to customary closing conditions, the Offering is expected to settle and close on or about June 15, 2020.

Catalent intends to use the net proceeds from the Offering to repay in full the $200 million of outstanding borrowings under the revolving credit facility under its senior secured credit facilities and for general corporate purposes, which may include, without limitation and in Catalent’s sole discretion, working capital, capital expenditures, and funding its growth strategy through organic investments and potential future acquisitions.

RBC Capital Markets is acting as sole underwriter for the Offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of common stock or any other security of Catalent in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.